The preclinical studies using different models of demyelinating diseases and data from MS patients suggest Nogo-A antibodies as a potential therapeutic approach for the treatment of relapsing-remitting MS (RRMS) and/or progressive forms of MS. The gene discussed is RTN4; the disease is myeloid sarcoma.